Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$33.09 USD

33.09
577,552

-0.54 (-1.61%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $33.13 +0.04 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?

by Zacks Equity Research

Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.

    Zacks Equity Research

    Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View

    by Zacks Equity Research

    Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.

      Arpita Dutt headshot

      Key Factors to Look Out for in Celgene's (CELG) Q1 Results

      by Arpita Dutt

      Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.

        Zacks Equity Research

        Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?

        by Zacks Equity Research

        Agios (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Zacks Equity Research

          Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up

          by Zacks Equity Research

          Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.

            Zacks Equity Research

            Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y

            by Zacks Equity Research

            Agios posted narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of $1.55 per share, and the company reported a loss of $1.34.

              Zacks Equity Research

              Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

              by Zacks Equity Research

              Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.

                Zacks Equity Research

                Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)

                by Zacks Equity Research

                Agios Pharmaceuticals (AGIO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                  Zacks Equity Research

                  Agios Stops Development of PKR Activator AG-519, Stock Falls

                  by Zacks Equity Research

                  Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.

                    Kevin Matras headshot

                    A Company's First Profit Can Mean Big Profits to Investors

                    by Kevin Matras

                    Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include OPHT, XNPT, OSUR, INCY and AGIO.